Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Baxter
AstraZeneca
Dow
Johnson and Johnson

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Litigation Details for AstraZeneca LP v. Sigmapharm Laboratories, LLC (D. Del. 2015)

See Plans and Pricing

« Back to Dashboard

AstraZeneca LP v. Sigmapharm Laboratories, LLC (D. Del. 2015)

Docket   Start Trial Date Filed 2015-10-30
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Richard Gibson Andrews
Jury Demand None Referred To
Parties AMNEAL PHARMACEUTICALS LLC; AMNEAL PHARMACEUTICALS OF NEW YORK LLC; APOTEX CORP.; APOTEX INC.; ASTRAZENECA AB; ASTRAZENECA LP; ASTRAZENECA PHARMACEUTICALS LP; ASTRAZENECA UK LIMITED; HEC PHARM CO. LTD.; HEC PHARM GROUP; HEC PHARM USA; INVAGEN PHARMACEUTICALS INC.; MYLAN PHARMACEUTICALS INC.; PRINSTON PHARMACEUTICAL INC.; SANDOZ INC.; SIGMAPHARM LABORATORIES, LLC; WATSON LABORATORIES INC.
Patents 6,251,910; 6,525,060; 7,250,419; 7,265,124; 8,425,934; RE46,276
Attorneys Aaron S. Lukas; Anne Shea Gaza; Barry P. Golob; Benjamin A. Smyth; Bindu Ann George Palapura; Daniel M. Silver; David Ellis Moore; Eric J. Choi; Gregory J. Brodzik; James H. Wallace , Jr.; James Michael Lennon; Jill K. MacAlpine; John C. Phillips , Jr.; Joseph James Bellew; Karen L. Pascale; Kelly E. Farnan; Kerry B. McTigue; Mark A. Pacella; Mark J. Feldstein; Michael P. Kelly; Pei-Ru Wey; R. Touhey Myer; Robert M. Vrana; Robert S. Silver; Ryan P. O'Quinn; Salvatore Guerriero; Stephen B. Brauerman; Wesley E. Weeks; William B. Coblentz
Link to Docket External link to docket
Small Molecule Drugs cited in AstraZeneca LP v. Sigmapharm Laboratories, LLC
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for AstraZeneca LP v. Sigmapharm Laboratories, LLC (D. Del. 2015)

Date Filed Document No. Description Snippet Link To Document
2017-02-21 165 of multiple terms in U.S. Patent Nos. 6,525,060 ("the '060 patent") and 7,265,124 ("…construction for multiple terms in U.S. Patent Nos. 6,525,060 and 7,265,124. Signed by Judge Richard G…as U.S. Patent No. RE46,276 ("the '276 patent"). The '060 and '276 patents share …infringe five of AstraZeneca's patents. (D.I. 1). 2 The patents-in-suit claim chemical compounds as…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which External link to document
2015-10-30 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,251,910; 6,525,060; 7,250,419… 30 October 2015 1:15-cv-01000-RGA Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Medtronic
Merck
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.